See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
NYBC Ventures is an early-stage life sciences investment fund launched by New York Blood Center Enterprises (NYBCe) with a $50M commitment, dedicated to accelerating innovations in blood and cellular therapies and related technologies. The fund invests in therapeutics, devices, and cutting-edge technologies addressing critical challenges in benign hematology, transfusion medicine, cell therapy, and infectious disease — including emerging areas such as in-vivo cell therapy, gene editing, iPSC, and regenerative medicine. Beyond capital, NYBC Ventures offers portfolio companies access to world-renowned researchers, cell manufacturing capacity, source materials, and deep domain expertise, positioning itself as a uniquely strategic partner for founders solving healthcare's most pressing challenges in blood and cell-based medicine.
Notable quotes
“This is the first venture fund solely dedicated to advancing innovation in blood and cell-based therapies and technologies. NYBC Ventures provides companies more than capital, offering access to world-renowned researchers and their labs, cell manufacturing capacity and source materials.”
“NYBC Ventures is dedicated to supporting early-stage innovation that will drive the next generation of transformative therapies to improve patient care and outcomes. With our deep expertise in blood and cellular therapies, we are a trusted partner to founders who are solving some of healthcare's biggest challenges, from new approaches to drug delivery and discovery, to the development of life-saving therapies.”
“John, Jung, Cristina, and David are not just leaders in their fields – they are visionaries with proven track records of driving strategic growth in the life sciences. Their guidance will be pivotal as we continue to support early and established companies advancing innovations in blood and cellular therapies.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Vitestro | Series B | $22m | 2026-03-02 |
| AvenCell Therapeutics | Series B | $112m | 2024-10-22 |
| Akadeum Life Sciences | Series B | $20m | 2025-04-25 |
| Immusoft | Venture | — | 2025-03-15 |
| ViTToria Biotherapeutics | Early Stage VC | — | 2024-11-12 |
| Functional Fluidics | Venture | — | 2024-11-22 |
| Thymmune Therapeutics | Seed | $7m | 2023-05-01 |
| KaloCyte | Seed | — | 2022-01-01 |
| STRM.Bio | Seed | — | 2023-05-01 |
| Catena Biosciences | Venture | — | 2023-05-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Novo Holdings | 1 |
| Blackstone Life Sciences | 1 |
| F-Prime Capital | 1 |
| Pillar VC | 1 |
| Arboretum Ventures | 1 |
| Sonder Capital | 1 |
Fit check
Is NYBC Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit